In part two of this two-part series, Dr. Vikram Karnik and Dr. Lorraine Kalia discuss the preclinical data and epidemiological data that led us to the phase three study on exenatide.
Show reference:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00161-8/abstract
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
